Cardio Diagnostics Holdings, Inc. Increase (Decrease) in Accounts Receivable
Cardio Diagnostics Holdings, Inc. (CDIO) reported Increase (Decrease) in Accounts Receivable of -$4.22 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-07
- Cardio Diagnostics Holdings, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$369.00, a 110.93% decline year-over-year.
- Cardio Diagnostics Holdings, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$3.85K.
- Cardio Diagnostics Holdings, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$3.10K, a 168.59% decline year-over-year.
- Cardio Diagnostics Holdings, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$1.71K, a 125.93% decline year-over-year.
- Cardio Diagnostics Holdings, Inc. increase (decrease) in accounts receivable for fiscal 2025 was -$10.49K, a 176.81% decline from fiscal 2024.
- Cardio Diagnostics Holdings, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $13.65K, a 175.24% increase from fiscal 2023.
- Cardio Diagnostics Holdings, Inc. increase (decrease) in accounts receivable for fiscal 2023 was $4.96K.
- Cardio Diagnostics Holdings, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$901.00, a 200.00% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$369.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$4.22K 10-Q · filed 2026-08-07 | -$7.32K derived: sum of 3 quarters · filed 2026-08-07 | -$9.02K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | -$3.85K 10-Q · filed 2026-05-15 | -$6.95K derived: sum of 2 quarters · filed 2026-05-15 | -$8.65K derived: sum of 3 quarters · filed 2026-05-15 | -$5.28K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$3.10K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$4.80K derived: sum of 2 quarters · filed 2026-03-13 | -$1.43K derived: sum of 3 quarters · filed 2026-08-07 | -$10.49K 10-K · filed 2026-03-13 |
| 2025-09-30 | -$1.71K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.67K derived: sum of 2 quarters · filed 2026-08-07 | -$7.39K 10-Q · filed 2025-11-12 | -$2.88K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $3.38K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | -$5.68K 10-Q · filed 2026-08-07 | -$1.17K derived: sum of 3 quarters · filed 2026-08-07 | $5.41K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | -$9.06K 10-Q · filed 2026-05-15 | -$4.55K derived: sum of 2 quarters · filed 2026-05-15 | $2.03K derived: sum of 3 quarters · filed 2026-05-15 | -$9.44K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $4.51K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $11.09K derived: sum of 2 quarters · filed 2026-03-13 | -$376.00 derived: sum of 3 quarters · filed 2026-03-13 | $13.65K 10-K · filed 2026-03-13 |
| 2024-09-30 | $6.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$4.89K derived: sum of 2 quarters · filed 2025-11-12 | $9.14K 10-Q · filed 2025-11-12 | $13.75K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$11.47K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.56K 10-Q · filed 2025-08-14 | $7.17K derived: sum of 3 quarters · filed 2025-08-14 | $6.47K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $14.03K 10-Q · filed 2025-05-15 | $18.64K derived: sum of 2 quarters · filed 2025-05-15 | $17.94K derived: sum of 3 quarters · filed 2025-05-15 | $18.99K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $4.61K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.91K derived: sum of 2 quarters · filed 2025-03-20 | $4.96K derived: sum of 3 quarters · filed 2025-03-20 | $4.96K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$700.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $350.00 derived: sum of 2 quarters · filed 2024-11-13 | $350.00 10-Q · filed 2024-11-13 | $350.00 derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $1.05K 10-Q · filed 2024-08-12 | $1.05K derived: sum of 3 quarters · filed 2024-08-12 | $1.05K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $0.00 derived: sum of 3 quarters · filed 2024-04-01 | $0.00 derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | $0.00 derived: sum of 3 quarters · filed 2024-04-01 | -$901.00 10-K · filed 2024-04-01 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | -$901.00 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$901.00 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | -$901.00 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $901.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |